James C. Lim Sells 5,189 Shares of Becton Dickinson and Co (BDX) Stock

Becton Dickinson and Co (NYSE:BDX) EVP James C. Lim sold 5,189 shares of the company’s stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $242.36, for a total value of $1,257,606.04. Following the completion of the transaction, the executive vice president now directly owns 13,318 shares of the company’s stock, valued at approximately $3,227,750.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of BDX stock opened at $243.26 on Friday. Becton Dickinson and Co has a one year low of $209.91 and a one year high of $265.87. The company has a market capitalization of $64.40 billion, a P/E ratio of 22.09, a P/E/G ratio of 1.44 and a beta of 1.19. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.93. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The business had revenue of $4.40 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the prior year, the business posted $2.40 earnings per share. The firm’s revenue was up 39.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Becton Dickinson and Co will post 12.28 EPS for the current fiscal year.

Several research firms have recently issued reports on BDX. Barclays set a $260.00 price objective on Becton Dickinson and and gave the company a “hold” rating in a research note on Thursday. Citigroup upped their price objective on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. Piper Jaffray Companies lowered their price objective on Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a research note on Tuesday. Royal Bank of Canada reaffirmed a “hold” rating and issued a $248.00 price objective on shares of Becton Dickinson and in a research note on Friday, August 3rd. Finally, Morgan Stanley upped their price objective on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research note on Thursday, October 4th. Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $254.07.

Hedge funds have recently made changes to their positions in the stock. Winslow Capital Management LLC boosted its holdings in shares of Becton Dickinson and by 5.6% during the 3rd quarter. Winslow Capital Management LLC now owns 976,540 shares of the medical instruments supplier’s stock worth $254,878,000 after buying an additional 52,004 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Becton Dickinson and during the 3rd quarter worth approximately $525,000. DekaBank Deutsche Girozentrale boosted its holdings in shares of Becton Dickinson and by 0.7% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 242,427 shares of the medical instruments supplier’s stock worth $63,408,000 after buying an additional 1,668 shares in the last quarter. Pathstone Family Office LLC boosted its holdings in shares of Becton Dickinson and by 41.0% during the 3rd quarter. Pathstone Family Office LLC now owns 11,693 shares of the medical instruments supplier’s stock worth $3,051,000 after buying an additional 3,403 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board boosted its holdings in shares of Becton Dickinson and by 1.6% during the 3rd quarter. Ontario Teachers Pension Plan Board now owns 110,879 shares of the medical instruments supplier’s stock worth $28,939,000 after buying an additional 1,714 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

WARNING: This piece of content was reported by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.wkrb13.com/2018/11/10/james-c-lim-sells-5189-shares-of-becton-dickinson-and-co-bdx-stock.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Further Reading: Are Wall Street analysts’ stock ratings worth following?

Insider Buying and Selling by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply